HEPA (Hepion Pharmaceuticals) Debt-to-Equity: 0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Hepion Pharmaceuticals Debt-to-Equity?

Hepion Pharmaceuticals HEPA -12.16% Debt-to-Equity is 0.00 as of Jun. 2026. The stock has 2 warning signs investors should review. Among 956 Biotechnology companies, Hepion Pharmaceuticals ranks better than 75.1% on this metric.

Hepion Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.00 Mil. Hepion Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.00 Mil. Hepion Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $1.28 Mil. Hepion Pharmaceuticals's debt to equity for the quarter that ended in Jun. 2026 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Hepion Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

HEPA' s Debt-to-Equity Range Over the Past 10 Years
Min: -5.46   Med: 0.02   Max: 4.09
Current: 0.04

During the past 13 years, the highest Debt-to-Equity Ratio of Hepion Pharmaceuticals was 4.09. The lowest was -5.46. And the median was 0.02.

HEPA's Debt-to-Equity is ranked better than
75.1% of 956 companies
in the Biotechnology industry
Industry Median: 0.16 vs HEPA: 0.04

Hepion Pharmaceuticals  (OTCPK:HEPA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Hepion Pharmaceuticals Debt-to-Equity Related Terms

Hepion Pharmaceuticals Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Hepion Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hepion Pharmaceuticals Debt-to-Equity Chart

Hepion Pharmaceuticals Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.03 -1.56 0.02

Hepion Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.06 0.02 0.00 0.00

HEPA vs MTNB, ITRMF, VIVS: Debt-to-Equity Comparison

For the Biotechnology subindustry, Hepion Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hepion Pharmaceuticals Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hepion Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Hepion Pharmaceuticals's Debt-to-Equity falls into.


Hepion Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Hepion Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.054 + 0) / 2.668
=0.02

Hepion Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Jun. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 1.279
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Hepion Pharmaceuticals (HEPA) has a Debt-to-Equity of 0.00 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Hepion Pharmaceuticals and its competitors. According to the industry distribution chart, Hepion Pharmaceuticals ranks #238 out of 956 companies in the Biotechnology industry, placing it in the top 24.9%.
Is Hepion Pharmaceuticals' Debt-to-Equity too high?
Hepion Pharmaceuticals' current Debt-to-Equity is 0.00. Based on the distribution chart, Hepion Pharmaceuticals ranks #238 out of 956 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Hepion Pharmaceuticals' Debt-to-Equity compare to MTNB and ITRMF?
According to the Biotechnology industry distribution chart, Hepion Pharmaceuticals ranks #238 out of 956 companies for Debt-to-Equity. This places Hepion Pharmaceuticals in the top 25% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Hepion Pharmaceuticals and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hepion Pharmaceuticals's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hepion Pharmaceuticals stock overvalued right now?
Hepion Pharmaceuticals (HEPA) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Hepion Pharmaceuticals (HEPA), the current Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hepion Pharmaceuticals Business Description

Address 55 Madison Avenue, Suite 400- PMB 4362, Morristown, NJ, USA, 07960
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of drug therapy for the treatment of chronic liver diseases. The company is pioneering early cancer detection solutions with a novel liquid biopsy. diagnostics. The company's mission is to redefine the early detection of hepatocellular carcinoma, moving from missed diagnoses to timely, precise intervention. It's focused on delivering non-invasive, clinically grounded liquid biopsy solutions for patients at the highest risk, particularly those living with cirrhosis.